TITAN: Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

10-1074 - National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead

3BNC117 - Rockefeller University, Cornell University, Frontier Biotech, Gilead

lefitolimod (MGN1703) - Mologen, OncXerna Therap, iPharma

TITAN: Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (clinicaltrials.gov) - Apr 1, 2022 - P2a | N=47 | Active, not recruiting | Sponsor: University of Aarhus | Recruiting ➔ Active, not recruiting
Enrollment closed • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4

http://clinicaltrials.gov/ct2/show/NCT03837756

Apr 1, 2022